Drugs / GRIDEGALUTAMIDE
GRIDEGALUTAMIDE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06433505 | May 2024 → Feb 2025 | — | Celgene Corporation | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04428788 Background | Jun 2020 → Oct 2025 | prostate neoplasm | Celgene Corporation | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GRIDEGALUTAMIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068413 ↗ |
| Known as | BMS-986409 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06433505 ↗ |
| Known as | CC-94676, (3R)- | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068413 ↗ |
| Known as | CC1083611 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04428788 ↗ |
| Known as | CEL-010355 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068413 ↗ |
| Known as | Gridegalutamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068413 ↗ |
| Modality | Small molecule | — CHEMBL6068413 ↗ |